- Home
- LUCY vs LGVN Comparison
LUCY vs LGVN Comparison
Compare LUCY & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | LGVN |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 12.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUCY | LGVN |
|---|---|---|
| Price | $1.15 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 217.1K | ★ 368.1K |
| Earning Date | 11-13-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,392,547.00 | $1,437,000.00 |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.22 | N/A |
| 52 Week Low | $0.95 | $0.49 |
| 52 Week High | $7.08 | $2.24 |
Technical Indicators
Market Signals| Indicator | LUCY | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 49.59 |
| Support Level | $1.36 | $0.49 |
| Resistance Level | $1.17 | $0.60 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 39.58 | 69.70 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.